Recently, Medtronic announced that its infused bone graft stent has received approval from the Australian Therapeutic Goods Administration (TGA). This regulatory clearance allows the company to market and sell the infused bone graft stent, known as LT-CAGE, across Australia. The device is designed for use in spinal fusion procedures, offering a novel approach to treating degenerative disc conditions.
The LT-CAGE system is an internal fixation device that combines a small, hollow, threaded metal cone with a bone graft structure. It is specifically engineered to address disc degeneration by restoring the natural height of the affected intervertebral space. By doing so, it helps alleviate pressure on compressed nerves, thereby reducing symptoms associated with lumbar spine degeneration such as pain, numbness, and weakness.
This innovative technology provides a more effective and minimally invasive option for patients suffering from chronic back pain caused by disc deterioration. With its recent TGA approval, Medtronic is now able to expand its reach in the Australian market, offering a new solution that could improve patient outcomes and reduce recovery times. The LT-CAGE represents a significant advancement in spinal care, combining structural support with biological integration to promote long-term healing and stability.
Ingredients For Water Treatment
CAS NO 556-50-3 Glycylglycine,Sodium persulfate,Potassium bromide,Sulfamic acid
Ronas Chemicals Ind. Co.,Ltd. , https://www.ronaschemical-cn.com